A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.

NCT03681548 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer Recurrent

Interventions

DRUG: Doxorubicin Hydrochloride Liposome Injection

Sponsor

Ayana Pharma Ltd.,

Collaborators

[object Object]